Poseida Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

17.05.22	Poseida Therapeutics Presents Encouraging Preclinical Data Highlighting P-ckit-ALLO1 at the ASGCT 2022 Annual Meeting (PR Newswire)
12.05.22	Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2022 (PR Newswire)
02.05.22	Poseida Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting (PR Newswire)
28.04.22	Poseida Therapeutics to Present at BofA Securities 2022 Healthcare Conference (PR Newswire)
10.03.22	Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2021 (PR Newswire)
02.03.22	Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
23.02.22	Poseida Therapeutics Hosts Second Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations (PR Newswire)
22.02.22	Poseida Therapeutics Appoints Brent Warner as President, Gene Therapy (PR Newswire)
17.02.22	Poseida Therapeutics to Present Interim Results from Phase 1 Trial of P-PSMA-101 at ASCO Genitourinary Cancers Symposium (PR Newswire)
09.02.22	Poseida Therapeutics to Host Virtual R&D Day on February 23, 2022 (PR Newswire)
10.01.22	Poseida Therapeutics Announces Eric Ostertag to Serve as Executive Chairman and Transition Role of CEO to Current President and CBO Mark Gergen (PR Newswire)
20.12.21	Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-MUC1C-ALLO1, a Fully Allogeneic CAR-T Targeting Multiple Solid Tumors (PR Newswire)
13.12.21	Poseida Therapeutics Provides Update on BCMA-Targeted CAR-T Clinical Trials at the 2021 American Society of Hematology (ASH) Annual Meeting (PR Newswire)
09.11.21	Poseida Therapeutics Provides Program Updates and Financial Results for the Third Quarter of 2021 (PR Newswire)
09.11.21	Poseida Therapeutics to Present Preclinical Data Highlighting Fully Allogeneic CAR-T Product Candidates at the Society for Immunotherapy of Cancer 2021 Annual Meeting (PR Newswire)
03.11.21	Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences (PR Newswire)
13.10.21	Poseida Therapeutics Announces Leadership Appointments (PR Newswire)
12.10.21	Poseida Therapeutics Announces Research Collaboration with Takeda for Novel Non-Viral In Vivo Gene Therapies (PR Newswire)
01.10.21	Poseida Therapeutics to Present at Society for Immunotherapy of Cancer 2021 Annual Meeting (PR Newswire)
07.09.21	Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences (PR Newswire)
31.08.21	Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR-TCR Summit (PR Newswire)
30.08.21	Poseida: FDA Clears IND Application Of P-BCMA-ALLO1 On Relapsed/Refractory Multiple Myeloma (RTTNews)
30.08.21	Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma (PR Newswire)
12.08.21	Poseida Therapeutics Reports Program Updates and Financial Results for the Second Quarter of 2021 (PR Newswire)
26.07.21	Poseida Therapeutics Appoints Cynthia Collins to Board of Directors (PR Newswire)
06.01.21	IPO Lockup Expiration Alert: Poseida Therapeutics (PSTX) (RTTNews)
18.08.20	Stock Alert: Poseida Therapeutics Plunges 30% After FDA Decision (RTTNews)
18.08.20	NVAX Begins Vaccine Trial In S.Africa, PSTX Slapped With Clinical Hold, UTHR To Face FDA In Apr. (RTTNews)
17.08.20	FDA Halts Poseida Therapeutics' Prostate Cancer Drug Trial After Patient Dies; Shares Tank 35% (RTTNews)
10.07.20	Poseida Therapeutics Prices Upsized IPO Of 14 Mln Shares At $16/Shr (RTTNews)
09.07.20	Healthcare IPOs For July 10 (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Novartis	95.58	1.90 %	K V
Logitech Intl	91.48	1.35 %	K V
Part Grp Hldg	1’393.00	1.20 %	K V
Roche Hldg G	286.00	0.28 %	K V
Sonova Hldg	319.20	0.16 %	K V
Swiss Re	139.40	-0.50 %	K V
Zurich Insur Gr	553.80	-0.54 %	K V
Kuehne+Nagel Int	207.60	-0.76 %	K V
Lonza Grp	582.00	-1.49 %	K V
Nestle	77.48	-1.53 %	K V

Nachrichten zu Poseida Therapeutics Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten